Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Douglas A. Katsev, MD, discusses ...
Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...
Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy ...
Because the condition was bilateral, a corneal dystrophy was suspected. Lattice dystrophy typically presents with branching refractile lattice lines with intervening haze, which are observed best ...
Québec City, April 14, 2023 - Fuchs' endothelial corneal dystrophy, a degenerative eye disease, causes progressive vision loss that can induce blindness. It is the leading cause of corneal ...
CHICAGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 ...
Add Yahoo as a preferred source to see more of our stories on Google. In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results